Loading...

Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: The assessment of the added therapeutic value of new medicines with a new active substance is hampered by the lack of appropriate comparative information. Though the extent of this information gap is generally perceived as substantial, it has not been quanti...

Full description

Saved in:
Bibliographic Details
Main Authors: van Luijn, Johan C F, Gribnau, Frank W J, Leufkens, Hubert G M
Format: Artigo
Language:Inglês
Published: Blackwell Science Inc 2007
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2000577/
https://ncbi.nlm.nih.gov/pubmed/17166187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2006.02812.x
Tags: Add Tag
No Tags, Be the first to tag this record!